+

ES2121788T3 - Anticuerpos dirigidos contra cd3. - Google Patents

Anticuerpos dirigidos contra cd3.

Info

Publication number
ES2121788T3
ES2121788T3 ES91917169T ES91917169T ES2121788T3 ES 2121788 T3 ES2121788 T3 ES 2121788T3 ES 91917169 T ES91917169 T ES 91917169T ES 91917169 T ES91917169 T ES 91917169T ES 2121788 T3 ES2121788 T3 ES 2121788T3
Authority
ES
Spain
Prior art keywords
ser
tyr
gly
asp
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91917169T
Other languages
English (en)
Inventor
Scott David Gorman
Edward Graham Routledge
Herman Waldmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BTG International Ltd
Original Assignee
BTG International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BTG International Ltd filed Critical BTG International Ltd
Application granted granted Critical
Publication of ES2121788T3 publication Critical patent/ES2121788T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LIGANTES CON UNA AFINIDAD DE ENLACE PARA EL ANTIGENO CD3 QUE TIENEN, AL MENOS, UN CDR CUYO ORIGEN ES DISTINTO RESPECTO A LA REGION DE LA ESTRUCTURA VARIABLE Y/O A LA REGION CONSTANTE DEL LIGANTE; AL MENOS, EL UNICO CDR QUE SE SELECCIONA DE LAS SECUENCIAS DE AMINOACIDOS: (A) SER TR ARG ASN LIS FE DE LOS MISMOS, TIENEN VALOR TERAPEUTICO, PARTICULARMENTE EN EL CONTROL DEL RECHAZO A INJERTOS.
ES91917169T 1990-10-05 1991-10-04 Anticuerpos dirigidos contra cd3. Expired - Lifetime ES2121788T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909021679A GB9021679D0 (en) 1990-10-05 1990-10-05 Antibody preparation

Publications (1)

Publication Number Publication Date
ES2121788T3 true ES2121788T3 (es) 1998-12-16

Family

ID=10683287

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91917169T Expired - Lifetime ES2121788T3 (es) 1990-10-05 1991-10-04 Anticuerpos dirigidos contra cd3.

Country Status (12)

Country Link
EP (1) EP0504350B1 (es)
JP (1) JP3081641B2 (es)
KR (1) KR100245564B1 (es)
AT (1) ATE169058T1 (es)
AU (1) AU651623B2 (es)
CA (1) CA2070659C (es)
DE (1) DE69129896T2 (es)
ES (1) ES2121788T3 (es)
GB (2) GB9021679D0 (es)
NZ (1) NZ240080A (es)
WO (1) WO1992006193A1 (es)
ZA (1) ZA917960B (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
US6129916A (en) * 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
US6106835A (en) * 1991-04-19 2000-08-22 Tanox, Inc. Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
US5872222A (en) * 1991-04-19 1999-02-16 Tanox Biosystems, Inc. Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
US5817308A (en) 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
WO1998049311A2 (en) 1997-04-30 1998-11-05 De Novo Enzyme Corporation Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
US6103466A (en) * 1997-07-14 2000-08-15 University Of Liege Double-muscling in mammals
ES2547858T3 (es) 1997-07-14 2015-10-09 Université de Liège Doble musculación en mamíferos
GB9815909D0 (en) 1998-07-21 1998-09-16 Btg Int Ltd Antibody preparation
US6531125B1 (en) 1999-03-02 2003-03-11 Twinstrand Therapeutics Inc. Antiviral ricin-like proteins
CA2305716A1 (en) 1999-05-28 2000-11-28 University Of Guelph Method for assay of wbpm
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
CA2482810C (en) 2002-05-02 2014-06-10 David Lovejoy Teneurin c-terminal associated peptides (tcap) and methods and uses thereof
CA2534382C (en) 2003-08-04 2018-12-11 The Hospital For Sick Children Epm2b gene mutations associated with lafora's disease
US7427670B2 (en) 2003-12-19 2008-09-23 Cytochroma Inc. Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
ATE530198T1 (de) 2005-02-16 2011-11-15 Univ Zuerich Verfahren zur behandlung von krebs unter verwendung eines immunotoxins mit einer exotoxin- a-gruppierung, bei der eine furinschnittstelle durch eine von mmp-2 oder mmp-9 gespaltene krebsassoziierte proteasestelle ersetzt ist
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
EP2041270B1 (en) 2006-07-13 2013-11-20 Wyeth LLC Production of glycoproteins
TWI522366B (zh) * 2006-10-02 2016-02-21 Ｅ Ｒ 施貴寶＆聖斯有限責任公司 與ｃｘｃｒ４結合之人抗體及彼之用途
WO2008045563A2 (en) 2006-10-12 2008-04-17 Wyeth Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
CA2666317C (en) 2006-11-03 2013-08-06 Wyeth Glycolysis-inhibiting substances in cell culture
CA2669084A1 (en) 2006-11-10 2008-05-29 Massachusetts Institute Of Technology Pak modulators
DE102006062398A1 (de) 2006-12-20 2008-06-26 Edi (Experimentelle & Diagnostische Immunologie) Gmbh Verfahren zur Erkennung und/oder Charakterisierung zellulärer Aktivitätsmuster, Verwendung von Toll-like-Rezeptor-Liganden (TLR-Liganden) und ein Kit
MX2009009240A (es) 2007-03-02 2009-09-08 Wyeth Corp Uso de cobre y glutamato en el cultivo celular para la produccion de polipeptidos.
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
EP2344180A2 (en) 2008-09-23 2011-07-20 Wyeth LLC Methods for predicting production of activating signals by cross-linked binding proteins
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
RU2481824C2 (ru) 2008-10-29 2013-05-20 Аблинкс Н.В Препараты однодоменных антигенсвязывающих молекул
US9085795B2 (en) 2009-02-04 2015-07-21 Molecular Innovations, Inc. Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
AU2010241706B2 (en) 2009-04-29 2015-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. ERG monoclonal antibodies
US20120226119A1 (en) 2009-07-09 2012-09-06 Hoffmann-La Roche Inc. Vivo tumor vasculature imaging
JP6190113B2 (ja) 2010-03-03 2017-08-30 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア オリゴマー特異アミロイドベータエピトープおよび抗体
JP2013536175A (ja) 2010-07-16 2013-09-19 アブリンクス エン．ヴェー． 修飾された単一ドメイン抗原結合分子及びその使用
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
EP2606119A1 (en) 2010-08-20 2013-06-26 Wyeth LLC Cell culture of growth factor-free adapted cells
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
MX361242B (es) 2011-03-30 2018-11-30 Ablynx Nv Anticuerpos de dominio sencillo contra tnf-alfa y usos de los mismos.
KR20140077977A (ko) 2011-10-21 2014-06-24 화이자 인코포레이티드 철을 첨가하여 세포 배양을 개선하는 방법
EP3718556A3 (en) 2012-08-31 2020-12-30 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
EP4088737A3 (en) 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
CA2886120A1 (en) 2012-10-08 2014-04-17 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
HK1216153A1 (zh) 2012-12-13 2016-10-21 University Of Virginia Patent Foundation 用於卵巢癌治療和診斷的靶向肽
CN113150164A (zh) 2013-07-25 2021-07-23 西托姆克斯治疗公司 多特异性抗体、多特异性可活化抗体及其使用方法
WO2015140708A1 (en) 2014-03-19 2015-09-24 Pfizer Inc. Method of cell culture
AU2015247727A1 (en) 2014-04-15 2016-11-03 University Of Virginia Patent Foundation Isolated T cell receptors and methods of use therefor
BR112017001579A2 (pt) 2014-07-25 2017-11-21 Cytomx Therapeutics Inc anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
MA45352A (fr) 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
EP3353313B1 (en) 2015-09-23 2024-08-07 Pfizer Inc. Cells and method of cell culture
GB201520191D0 (en) 2015-11-16 2015-12-30 Cancer Rec Tech Ltd T-cell receptor and uses thereof
AU2017247701B2 (en) 2016-04-05 2022-11-10 Pfizer Inc. Cell culture process
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
US20200056190A1 (en) 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
CN111868223A (zh) 2017-09-15 2020-10-30 百时美施贵宝公司 大规模生产目的多肽过程中的在线生物质电容监测
US12239736B2 (en) 2018-01-25 2025-03-04 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
EP3765076A1 (en) 2018-03-16 2021-01-20 Bristol-Myers Squibb Company Metabolic enzyme activity and disulfide bond reduction during protein production
JP7672150B2 (ja) 2018-03-26 2025-05-07 グリカノスティックス エス・アール・オー タンパク質糖鎖プロファイリングの手段及び方法
EP3849600A1 (en) 2018-09-12 2021-07-21 ACM Biolabs Pte Ltd Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
CA3121884A1 (en) 2018-12-06 2020-06-11 Pfizer Inc. Cells with reduced inhibitor production and methods of use thereof
US20220332799A1 (en) 2019-09-04 2022-10-20 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Herv inhibitors for use in treating tauopathies
WO2022218957A1 (en) 2021-04-12 2022-10-20 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
US20240377402A1 (en) 2021-08-26 2024-11-14 Glycanostics, S.R.O. Glycoprotein biomarkers for diagnosing cancer
CA3231890A1 (en) 2021-09-14 2023-03-23 Jan Tkac Use of lectins to determine mammaglobin-a glycoforms in breast cancer
WO2023079058A1 (en) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Cell culture with reduced production of lactate
EP4473096A1 (en) 2022-02-02 2024-12-11 Pfizer Inc. Cysteine prototrophy
CN115073602B (zh) * 2022-05-30 2023-10-03 苏州百道医疗科技有限公司 一种抗cd3重组兔单克隆抗体及其应用
WO2024218706A1 (en) 2023-04-21 2024-10-24 Pfizer Inc. Improved cells and cell cultures

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI105320B (fi) * 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9021679D0 (en) * 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation

Also Published As

Publication number Publication date
GB9021679D0 (en) 1990-11-21
GB2249310B (en) 1994-08-03
DE69129896T2 (de) 1998-12-10
EP0504350A1 (en) 1992-09-23
DE69129896D1 (de) 1998-09-03
WO1992006193A1 (en) 1992-04-16
EP0504350B1 (en) 1998-07-29
JP3081641B2 (ja) 2000-08-28
KR927003816A (ko) 1992-12-18
ZA917960B (en) 1993-04-05
NZ240080A (en) 1995-05-26
ATE169058T1 (de) 1998-08-15
JPH05502384A (ja) 1993-04-28
GB9121126D0 (en) 1991-11-13
AU651623B2 (en) 1994-07-28
KR100245564B1 (ko) 2000-02-15
CA2070659A1 (en) 1992-04-06
AU8546891A (en) 1992-04-28
GB2249310A (en) 1992-05-06
CA2070659C (en) 2001-04-24

Similar Documents

Publication Publication Date Title
ES2121788T3 (es) Anticuerpos dirigidos contra cd3.
ATE384792T1 (de) Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
DK0724456T3 (da) CD40-Antistoffer
CA2212750A1 (en) Humanized antibodies against cd3
ATE301471T1 (de) Verwendung von antikörpen gegen cd45ro leukozytenantigen zur immunmodulation
SE9304060D0 (sv) Sätt att selektera specifika bakteriofager
GR1002306B (el) Αναλυση και διαταξη συγκολλησεως στηλης.
LT96115A (en) Immuno-stimulatory monoclonal antibodies
DE69129460D1 (de) Verwendung von Anti-ICAM Antikörpern zur Herstellung eines Präparats für die BEHANDLUNG VON ENDOTOXINSCHOCK
GR3018371T3 (en) Method for identifying or determining proteins and applications therefor.
DK0812206T3 (da) Fremgangsmåde til stimulering af en immunrespons
HU9602570D0 (en) Process for producing immunoglobulines from fractions produced with fractioning human blood-plasma
ATE191568T1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
DE3485712D1 (de) Monoklonale antikoerper gegen menschliche nierenkrebsantigene und verfahren.
DE3888604D1 (de) Monoklonale Antikörper gegen Antithrombinbindende Substanz und seine Verwendungen.
DE3570677D1 (en) Acino-foetal differentiation proteins associated with cancer of the pancreas, antiserum and monoclonal antibodies against these proteins and processes for their preparation
EP0491310A3 (en) Method for the determination of antibodies against lipocortine
CA2095735A1 (en) Monoclonal antibodies to hepatitis c virus and method for using same
DE59207362D1 (de) Monoklonale Antikörper gegen den Plasmin-Antiplasmin Komplex, Verfahren zu ihrer Herstellung sowie ihre Verwendung
DK494084A (da) Hybridoma, monokloniske antistoffer frembragt hermed og diagnosemetode under anvendelse af disse
HUP0003029A2 (hu) Ankrod specifikus monoklonális antitestek, antitestfragmentumok, keverékeik és alkalmazásuk
ATE9845T1 (de) Verfahren zur bestimmung von antigenen, antikoerpern und deren komplexen.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 504350

Country of ref document: ES

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载